ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the usage of the “at-the market” equity of its providing plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti might issue and sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being sold at prevailing market costs averaging US$1.0747 per share. No securities had been sold in the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with their services. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and can provide the Company with extra freedom in its ongoing review process to check out and evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of efficacy as well as safety for lowering triglycerides in clients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that are not statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements include known and unknown risks, uncertainties, as well as other unknown elements that may cause the particular results of Acasti to be materially different from historical outcomes or from any later results expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, readers are actually urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the day of this press release. Forward-looking statements in this press release include, but aren’t restricted to, info or statements concerning Acasti’s strategy, succeeding operations and its review of strategic alternatives.
The forward looking assertions found in this specific press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward-Looking Statements” section contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor area of Acasti’s website at www.acastipharma.com. Most forward-looking claims in this press release are available as of the date of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a consequence of information that is new , future events or even otherwise, except as called for by law. The forward looking statements contained herein are also subject generally to risks and assumptions and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use